Glenmark Pharmaceuticals Inc, Paramus, NJ. RATIONALE: Seasonal allergic rhinitis (SAR) symptoms are troublesome and often impair quality of life (QoL). Demonstrated efficacy, safety and QoL of GSP301, a fixed-dose combination nasal spray containing olopatadine hydrochloride (antihistamine) and mometasone furoate (corticosteroid), have been reported previously. Pooled QoL analysis from 3 SAR studies conducted across different pollen seasons are presented here. METHODS: Twice-daily (BID) treatment results from double-blind, randomized, placebo-controlled 14-day studies (NCT02318303, NCT02631551, NCT02870205; N52,971) were pooled. SAR patients (12-65 years) were equally randomized to GSP301 (olopatadine 665mg/ mometasone 25mg BID), olopatadine (665mg BID), mometasone (25mg BID), or placebo (BID). Results from once-daily treatments, evaluated only in NCT02318303, are not shown here. Mean change from baseline to day 15 in overall Rhinoconjunctivitis Quality of Life QuestionnaireStandardized Activities [RQLQ(S)] score was analyzed using ANCOVA (P<0.055statistically significant). Individual QoL domains were also assessed. RESULTS: GSP301 BID demonstrated statistically significant improvements in overall RQLQ(S) scores vs placebo (least squares mean difference 3 Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South). RATIONALE: The total count and percentage of eosinophils in a nasal smear sample are useful for diagnosing allergic rhinitis. Although some studies have evaluated the presence of nasal eosinophilia for diagnosing allergic rhinitis, the use of this criterion is not sufficiently investigated. In addition, no study has determined the correlation between eosinophil count and percentage in sample nasal smears. Therefore, this study aimed to investigate the correlation between nasal eosinophil count and percent in patients with rhinitis. METHODS: This was a retrospective cohort study of patients with a clinical history of rhinitis, under 19 years of age, examined at an outpatient clinic of a tertiary referral hospital in Korea, between January and August 2017. Nasal smears of patients were obtained by swabbing the nasal inferior turbinate 3-4 times with a cotton swab. The sample was then placed on a glass slide and stained with Giemsa stain. All specimens were examined by the same pathologist, who was blinded to the clinical history of each patient. RESULTS: A total of 106 pediatric patients underwent nasal smear examinations. There was a positive correlation between the nasal eosinophil count and percentage in patients with rhinitis. Y 5 0.768 3 X + 0.280 (Y 5 eosinophil count; X 5 eosinophil percent). The cut-off value was based on the nasal eosinophil count (10 cells/high-powered field) or a nasal eosinophil percent >10% in the patients with allergic rhinitis. CONCLUSIONS: The nasal eosinophil count and percent can be useful tools for the diagnosis of allergic rhinitis in pediatric patients.
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Rapid 3 Glenmark Pharmaceuticals Inc, Paramus, NJ. RATIONALE: GSP301, a fixed-dose combination nasal spray containing olopatadine hydrochloride (antihistamine) and mometasone furoate (corticosteroid), was efficacious for treating seasonal allergic rhinitis (SAR) nasal and ocular symptoms, with a rapid onset of action (OOA), and was well tolerated (previously reported). Pooled analysis of OOA and ocular symptoms from 3 SAR studies are reported here. METHODS: Twice-daily (BID) treatment results were pooled from double-blind, randomized, placebo-controlled, 14-day studies (NCT02318303, NCT02631551, NCT02870205; N52,971). SAR patients (12-65 years) were equally randomized to GSP301 (olopatadine 665mg/ mometasone 25mg BID), olopatadine (665mg BID), mometasone (25mg BID), or placebo (BID). Results from once-daily treatments, evaluated only in NCT02318303, are not shown here. OOA (mean change from baseline in instantaneous Total Nasal Symptoms Scores from 15 minutes to 4 hours post-dose vs placebo) was analyzed using mixed-effect model repeated measures (MMRM; P<0.055statistically significant). Average of AM and PM 12-hour reflective Total Ocular Symptom Scores (rTOSS) was also assessed. RESULTS: GSP301 BID OOA was observed at 15 minutes post-dose (least squares mean difference [95% CI]: -0.23 [-0.41, -0 .05], P50.011); at all 9 subsequent timepoints, OOA was maintained and differences were clinically meaningful and significant (P<0.001, all). GSP301 significantly improved rTOSS vs placebo from baseline to day 14 (-0.47 [-0.66, -0 .28] P<0.001) and on each day (1-14; P<0.001, all). Treatment-emergent adverse events were low and comparable across treatments (reported elsewhere). CONCLUSIONS: GSP301 BID provided rapid OOA of 15 minutes, statistically significant ocular symptom improvements, and was well tolerated in a pooled analysis of SAR studies conducted across different pollen seasons.
